New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:24 EDTMDT, EWEdwards Lifesciences data to boost competitiveness, says Wells Fargo
Wells Fargo believes that data scheduled to be presented on March 30 will show that Edwards' (EW) Sapient XT has advantages over Medtronic's (MDT) CoreCalve, and will help Edwards compete more effectively with Medtronic in the U.S. The firm expects the American College of Cardiology's annual meeting from March 29-31 to boost adoption of TAVR products. It keeps Outperform ratings on both Edwards and Medtronic.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
16:55 EDTMDTFDA expands use of CoreValve System
Subscribe for More Information
09:04 EDTMDTMedtronic announces Japanese approval of CoreValue System
Subscribe for More Information
March 25, 2015
16:05 EDTMDTMedtronic highlights data on patients undergoing laparoscopic colon resections
Subscribe for More Information
March 24, 2015
10:08 EDTEWSenate Health, Education, Labor & Pensions Committee to hold a hearing
The Committee holds a hearing entitled, "Continuing America’s Leadership: Advancing Research and Development for Patients" with Chairman & CEO Mussallem of Edwards Lifesciences on March 24 at 10 am. Webcast Link
March 20, 2015
16:33 EDTEWStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
March 18, 2015
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use